And MARIPOSA evaluated the therapeutic efficacy of Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without Lazertinib in patients with EGFR-mutated (exon 19 deletions or L858R) locally advanced or metastatic NSCLC after disease progression on Osimertinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.